Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04373031
Title Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Providence Health & Services
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab

Cyclophosphamide + Doxorubicin + IRX-2 + Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.